Side-by-side · Research reference

KPVvsPTD-DBM

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED13/39 cited

BAnimal-StrongHUMAN-REVIEWED10/40 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

01Mechanism of Action

Parameter

KPV

PTD-DBM

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

CXXC5–Dishevelled protein-protein interaction

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Feedback intact?

No melanocortin receptor binding

Not applicable — pathway derepression rather than receptor agonism

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Antibody development

—

02Dosage Protocols

Parameter

KPV

PTD-DBM

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

—

Frequency

Daily or 2–3× per week

—

Lower / starter dose

100 mcg / day

—

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Animal models only (mice)

Duration

4–8 weeks per cycle

—

Reconstitution

Bacteriostatic water (SQ form)

—

Timing

No specific time; often taken with / before meals (oral)

—

Half-life

Hours (estimated; rapid tissue uptake)

—

Wound healing protocol

—

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

Hair regeneration protocol

—

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

Co-administration

—

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

Human translation

—

No published human studies

04Side Effects & Safety

Parameter

KPV

PTD-DBM

Injection site reaction

Mild irritation

—

GI symptoms

Rare nausea (oral form)

—

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

Unknown — no chronic dosing or human data

Pregnancy / OB

Avoid — insufficient data

—

Reported adverse events

—

None reported in animal studies

Wnt pathway activation risks

—

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

Delivery vehicle effects

—

HA-PG hydrogel well-tolerated in mice; human translation pending

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

05Administration Protocol

Parameter

KPV

PTD-DBM

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

3. Timing

Morning preferred; oral form taken with / before meals.

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Not disclosed in available literature. Peptide stability and storage conditions not published.

5. Needle

29–31G insulin syringe (SQ form).

—

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

PTD-DBM

— no documented stacks